权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Center for Cancer Experimental Therapeutics

癌症实验治疗中心

基本信息

批准号：
8129737
负责人：
BARBARA N TIMMERMANN
金额：
$ 109.15万
依托单位：
UNIVERSITY OF KANSAS LAWRENCE
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8129737
关键词：
Center Cancer Experimental Therapeutics

项目摘要

DESCRIPTION (provided by applicant): In this application we are requesting funds to continue our COBRE Center for Cancer Experimental Therapeutics (CCET) for five more years. Our center was among the first group of COBRE grants awarded in 2000. The mission of the CCET is to increase cancer-related research and NIH funding in the State of Kansas. It has been a very successful program (http://ccet.cobre.ku.edu/index.php). During the first ten years of the program our center has funded 26 full Project Awards and 27 smaller First Awards. Thirty tenure track assistant professors have received funding. Of these, 11 have been promoted with tenure and 12 are still on the tenure track. The CCET investigators have obtained 42 NIH-funded grants (17 ROIs) and 37 grants from other agencies, leading to a total of about $36,500,000 in new funding to Kansas. These investigators have published 218 journal and book manuscripts on research supported by the CCET. An essential part of our COBRE program was the establishment of two research cores, a High Throughput Screening (HTS) Core and a Medicinal Chemistry (IVIDC) Core. The COBRE Cores are located in the Structural Biology Center (SBC) located on the University of Kansas West Campus. The modern 4,500 sq.ft. High Throughput Screening Core research/office complex is fully equipped with state-of-the-art instrumentation and the personnel have extensive experience in executing cell-based, biochemical, labelfree, siRNA as well as high content screening campaigns. The primary goal of the HTS Core has been to make modern drug discovery tools available to biomedical researchers in the Greater Kansas City area, Kansas and beyond. The equally modern Medicinal Chemistry Core is housed in a laboratory of approximately 2000 square feet. The MDC Core works in conjunction with the HTS Core and in collaboration with COBRE investigators and other researchers. The tasks of the MDC Core are (1) to perform synthesis of known compounds necessary for biochemical studies, (2) to design and synthesize novel drug compounds as probes for ongoing studies, (3) to work with the HTS Core and its biology collaborators in carrying out optimization of hits obtained in screening campaigns, and (4) to synthesize fluorescent or affinity tagged analogs of existing probes when necessary for cell localization or target identification studies. In this Phase III application we are requesting funds to continue these successful research cores and to make them self-sustaining by the end of the five-year funding. In addition, we seek funding to support a Pilot Project program to help basic cancer research investigators obtain preliminary data to strengthen their applications to agencies for major funding. We plan to fund four projects per year. Finally, we request support for an Administrative Core to oversee the entire program, including the Pilot Project program and the two research cores. PUBLIC HEALTH RELEVANCE (provided by applicant): The mission of the CCET is to increase cancer-related research and NIH funding in the State of Kansas.

描述（由申请人提供）：在此申请中，我们要求资金继续我们的COBRE癌症实验治疗中心（CCET）五年。我们的中心是2000年第一批获得COBRE资助的中心之一。CCET的使命是增加堪萨斯州癌症相关研究和NIH的资金。这是一个非常成功的项目（http://ccet.cobre.ku.edu/index.php）。在该计划的前十年，我们中心已经资助了26个完整的项目奖和27个较小的一等奖。30位终身教授获得了资助。其中，11人获得了终身教职，12人仍在终身教职的轨道上。CCET的研究人员已经获得了42项nih资助的赠款（17项roi）和37项来自其他机构的赠款，总共为堪萨斯州提供了约3650万美元的新资金。这些研究人员发表了218篇由CCET支持的研究期刊和书籍手稿。我们COBRE项目的一个重要组成部分是建立了两个研究核心，一个高通量筛选（HTS）核心和一个药物化学（IVIDC）核心。COBRE核心位于堪萨斯大学西校区的结构生物学中心（SBC）。现代建筑面积为4500平方英尺。高通量筛选核心研究/办公大楼配备了最先进的仪器，员工在执行基于细胞、生化、无标签、siRNA以及高含量筛选活动方面拥有丰富的经验。HTS核心的主要目标是为大堪萨斯城地区、堪萨斯州及其他地区的生物医学研究人员提供现代药物发现工具。同样现代化的药物化学中心设在一个大约2000平方英尺的实验室里。MDC核心与HTS核心一起工作，并与COBRE调查人员和其他研究人员合作。MDC Core的任务是(1)合成生化研究所需的已知化合物，(2)设计和合成新型药物化合物作为正在进行的研究的探针，(3)与HTS Core及其生物学合作者合作，对筛选活动中获得的命中进行优化，以及(4)在细胞定位或目标识别研究所需时合成现有探针的荧光或亲和标记类似物。在第三阶段的申请中，我们要求拨款继续这些成功的研究核心，并在五年资助结束时使其自我维持。此外，我们寻求资金支持试点项目计划，以帮助基础癌症研究人员获得初步数据，以加强他们向机构申请主要资助。我们计划每年资助四个项目。最后，我们请求支持一个行政核心来监督整个计划，包括试点项目计划和两个研究核心。

项目成果

期刊论文数量（9）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

DOI：
10.1158/1535-7163.mct-12-0777
发表时间：
2013-03
期刊：
Molecular cancer therapeutics
影响因子：
5.7
作者：
Kambhampati S;Rajewski RA;Tanol M;Haque I;Das A;Banerjee S;Jha S;Burns D;Borrego-Diaz E;Van Veldhuizen PJ;Banerjee SK
通讯作者：
Banerjee SK

Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.

间隙连接增强剂增强顺铂在乳腺癌细胞中的细胞毒性。

DOI：
10.4172/1948-5956.1000170
发表时间：
2012
期刊：
Journal of cancer science & therapy
影响因子：
0
作者：
Ding,Ying;Nguyen,ThuAnnelise
通讯作者：
Nguyen,ThuAnnelise

Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface.

DOI：
10.1371/journal.pcbi.1002951
发表时间：
2013
期刊：
PLoS computational biology
影响因子：
4.3
作者：
Johnson DK;Karanicolas J
通讯作者：
Karanicolas J

Bioavailability and efficacy of a gap junction enhancer (PQ7) in a mouse mammary tumor model.

间隙连接增强剂 (PQ7) 在小鼠乳腺肿瘤模型中的生物利用度和功效。

DOI：
10.1371/journal.pone.0067174
发表时间：
2013
期刊：
PloS one
影响因子：
3.7
作者：
Shishido,StephanieN;Prasain,Keshar;Beck,Amanda;Nguyen,ThiDT;Hua,DuyH;Nguyen,ThuAnnelise
通讯作者：
Nguyen,ThuAnnelise

The anticancer effect of PQ1 in the MMTV-PyVT mouse model.